Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04810962
Other study ID # CPN-302
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 16, 2021
Est. completion date July 6, 2022

Study information

Verified date July 2023
Source Formosa Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion. The subjects will have undergone routine cataract surgery on Day 0 of the study and will be assessed the next day (Post-operative Day; POD1) after uncomplicated surgery for eligibility for randomization to study treatment. The study comprises the Main Study and the Endothelial Cell Sub-study.


Recruitment information / eligibility

Status Completed
Enrollment 370
Est. completion date July 6, 2022
Est. primary completion date July 6, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients 18 years of age or older expected to undergo unilateral uncomplicated cataract extraction via phacoemulsification and posterior chamber intraocular lens implantation in one eye. - Have a pin-hole corrected visual acuity without other correction of = 1.3 logarithm of the minimum angle of resolution (logMAR) in the study eye to be operated and contralateral eye as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Visit 1. - Willing and able to comply with study requirements and visit schedule. - Provide signed and dated informed consent. Exclusion Criteria: - Have a known sensitivity or allergy to clobetasol propionate, corticosteroids, or any of the study medication's components including benzalkonium chloride and soybean lecithin or any routine medication required during cataract surgery or for the conduct of study procedures - Have an ACC count > 0 or any evidence of intraocular inflammation (e.g., flare) in either eye at the Screening visit - Have a Grade > 0 on the Ocular Pain Assessment in either eye at the Screening visit Note: Other inclusion/exclusion criteria apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
APP13007, 0.05%
APP13007 eye drop, 0.05%
Matching Vehicle Placebo for APP13007, 0.05%
Matching vehicle placebo eye drop

Locations

Country Name City State
United States Dixon Eye Care Albany Georgia
United States Arizona Eye Center Chandler Arizona
United States Cincinnati Eye Institute Cincinnati Ohio
United States Rand Eye Institute Deerfield Beach Florida
United States Eye Associates for Fort Myers Fort Myers Florida
United States Fraser Eye Center Fraser Michigan
United States Orange County Ophthalmology Medical Group Garden Grove California
United States Chicago Cornea Consultants Hoffman Estates Illinois
United States Houston Eye Associates Houston Texas
United States Levenson Eye Associates Jacksonville Florida
United States Eye Care Specialists Kingston Pennsylvania
United States Carolina Cataract and Laser Center Ladson South Carolina
United States Wellish Vision Institute Las Vegas Nevada
United States Premiere Practice Management, LLC Los Angeles California
United States The Eye Care Center Louisville Kentucky
United States Carrot Eye Center Mesa Arizona
United States DCT-Shah Research Institute LLC dba Discovery Clinical Trials Mission Texas
United States Clayton Eye Clinical Research LLC Morrow Georgia
United States LoBue Laser and Eye Medical Center Inc Murrieta California
United States Visionary Research Institute Newport Beach California
United States Stiles Eyecare Excellence and Glaucoma Institute, PA Overland Park Kansas
United States Metropolitan Eye Research and Surgery Institute Palisades Park New Jersey
United States North Bay Eye Associates Petaluma California
United States Cornea and Cataract Consultants of Arizona Phoenix Arizona
United States Alterman, Modi and Wolter Poughkeepsie New York
United States Black Hills Regional Eye Institute Rapid City South Dakota
United States Round Rock Eye Consultants Round Rock Texas
United States Ophthalmology Associates Saint Louis Missouri
United States International Research Center Tampa Florida
United States Wolstan and Goldberg Eye Associates Torrance California
United States Michael K. Tran, MD, Inc. Westminster California

Sponsors (1)

Lead Sponsor Collaborator
Formosa Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Corneal Endothelial Cell Density - Mean Change From Screening to Postoperative Day 85 Corneal endothelial cell density in the Operated Study Eye (units: cells/mm2) was measured from the corneal endothelial cell images obtained using a specular microscope. Screening and Postoperative Day 85
Primary Participants With ACC Count = 0 in the Operated Study Eye at All Visits From Postoperative Day 8 Through Postoperative Day 15 Without Rescue Medication The number of cells in the anterior chamber of the eye are counted using slit-lamp biomicroscopy at each study visit and the results are reported as number of cells in a 1mm x 1mm area. Postoperative Day 8 and Postoperative Day 15
Primary Participants With Ocular Pain Grade = 0 in the Operated Study Eye at All Visits From Postoperative Day 4 Through Postoperative Day 15 Without Rescue Medication Ocular pain is measured in the eye using a subject-reported five-point (0-4) ocular pain grade scale (0 = no pain; 1 = minimal; 2 = mild; 3 = moderate; 4 = severe pain). Postoperative Day 4, Postoperative Day 8 and Postoperative Day 15
Primary Participants With Treatment-emergent Adverse Events (AEs) Number of participants with ocular and systemic treatment-emergent AEs. From First dose to Postoperative Day 22 (End of Main Study)
Secondary Participants With Anterior Chamber Cell Grade = 0 in the Operated Study Eye at POD8 Without Rescue Medication The number of cells in the anterior chamber of the eye are counted using slit-lamp biomicroscopy at each study visit and the results are reported as number of cells in a 1mm x 1mm area.ACC Grade 0 = 0 cells, ACC grade 1 = 1-5 cells, ACC grade 2 = 6-15 cells, ACC grade 3 = 16-30 cells, ACC grade 4 = >30 cells. Postoperative Day 8
Secondary Participants With Anterior Chamber Cell Grade = 0 in the Operated Study Eye at POD15 Without Rescue Medication The number of cells in the anterior chamber of the eye are counted using slit-lamp biomicroscopy at each study visit and the results are reported as number of cells in a 1mm x 1mm area. ACC Grade 0 = 0 cells, ACC grade 1 = 1-5 cells, ACC grade 2 = 6-15 cells, ACC grade 3 = 16-30 cells, ACC grade 4 = >30 cells. Postoperative Day 15
Secondary Participants With Ocular Pain Grade = 0 in the Operated Study Eye at POD4 Without Rescue Medication Ocular pain is measured in the eye using a subject-reported five-point (0-4) ocular pain grade scale (0 = no pain; 4 = severe pain). Postoperative Day 4
Secondary Participants With Ocular Pain Grade = 0 in the Operated Study Eye at POD8 Without Rescue Medication Ocular pain is measured in the eye using a subject-reported five-point (0-4) ocular pain grade scale (0 = no pain; 4 = severe pain). Postoperative Day 8
Secondary Participants With Ocular Pain Grade = 0 in the Operated Study Eye at POD15 Without Rescue Medication Ocular pain is measured in the eye using a subject-reported five-point (0-4) ocular pain grade scale (0 = no pain; 4 = severe pain). Postoperative Day 15
Secondary Participants With Anterior Chamber Flare (ACF) = 0 in the Operated Study Eye at POD4 Without Rescue Medication The degree of turbidity (flare) in the anterior chamber of the eye is measured using slit-lamp biomicroscopy and quantified on a five-point (0-4) anterior chamber flare grade scale (0 = none; 4 = Intense). Postoperative Day 4
Secondary Participants With Anterior Chamber Flare (ACF) = 0 in the Operated Study Eye at POD8 Without Rescue Medication The degree of turbidity (flare) in the anterior chamber of the eye is measured using slit-lamp biomicroscopy and quantified on a five-point (0-4) anterior chamber flare grade scale (0 = none; 4 = Intense). Postoperative Day 8
Secondary Participants With Anterior Chamber Flare (ACF) = 0 in the Operated Study Eye at POD15 Without Rescue Medication The degree of turbidity (flare) in the anterior chamber of the eye is measured using slit-lamp biomicroscopy and quantified on a five-point (0-4) anterior chamber flare grade scale (0 = none; 4 = Intense). Postoperative Day 15
Secondary Anterior Chamber Cell Grade in the Operated Study Eye - Change From Baseline (POD1 Prior to Dosing) to POD 15 The number of cells in the anterior chamber of the eye are counted using slit-lamp biomicroscopy and the results are reported as number of cells in a 1mm x 1mm area using a 5 point grading scale. ACC Grade 0 = 0 cells, ACC grade 1 = 1-5 cells, ACC grade 2 = 6-15 cells, ACC grade 3 = 16-30 cells, ACC grade 4 = >30 cells Baseline and Postoperative Day 15
Secondary Ocular Pain Grade in the Operated Study Eye - Change From Baseline (POD1 Prior to Dosing) to POD 15 Ocular pain is measured in the eye using a subject-reported five-point (0-4) ocular pain grade scale (0 = no pain; 1 = minimal; 2 = mild; 3 = moderate; 4 = severe pain). Baseline and Postoperative Day 15
Secondary Anterior Chamber Flare (ACF) in the Operated Study Eye - Change From Baseline (POD1 Prior to Dosing) to POD 15 The degree of turbidity (flare) in the anterior chamber of the eye is measured using slit-lamp biomicroscopy and quantified on a five-point (0-4) anterior chamber flare grade scale (0 = none; 1 = faint; 2 = moderate; 3 = marked; 4 = Intense). Baseline and Postoperative Day 15
Secondary Best Corrected Visual Acuity in the Operated Study Eye - Change From Baseline (POD1 Prior to Dosing) to POD4 The visual acuity in each eye is corrected using the pinhole method and the acuity is quantified on a logMAR (minimal angle of resolution) scale using the 'Early Treatment Diabetic Retinopathy Study' [ETDRS] charts for right and left eyes. A logMAR Score is calculated using the letter row on the chart and the number of incorrect letters read by the participant. Baseline and Postoperative Day 4
Secondary Best Corrected Visual Acuity in the Operated Study Eye - Change From Baseline (POD1 Prior to Dosing) to POD8 The visual acuity in each eye is corrected using the pinhole method and the acuity is quantified on a logMAR (minimal angle of resolution) scale using the 'Early Treatment Diabetic Retinopathy Study' [ETDRS] charts for right and left eyes. A logMAR Score is calculated using the letter row on the chart and the number of incorrect letters read by the participant. Baseline and Postoperative Day 8
Secondary Best Corrected Visual Acuity in the Operated Study Eye - Change From Baseline (POD1 Prior to Dosing) to POD15 The visual acuity in each eye is corrected using the pinhole method and the acuity is quantified on a logMAR (minimal angle of resolution) scale using the 'Early Treatment Diabetic Retinopathy Study' [ETDRS] charts for right and left eyes. A logMAR Score is calculated using the letter row on the chart and the number of incorrect letters read by the participant. Baseline and Postoperative Day 15
Secondary Participants Using of Anti-inflammatory 'Rescue' Medication Through End-of-Treatment Participants who do not respond to study treatment after randomization are started on anti-inflammatory medication (referred to as 'Rescue' medication). The number of subjects starting 'Rescue' medication is recorded at each study visit First dose to Postoperative Day 15
See also
  Status Clinical Trial Phase
Completed NCT04089735 - A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery Phase 2